Evidence map›Paper›PMID 32405978›Full record

ArticleAnnals of surgical oncology2020

Predictions of Pathological Features and Recurrence Based on FDG-PET Findings of Esophageal Squamous Cell Carcinoma after Trimodal Therapy.

Yoichi Hamai, Manabu Emi, Yuta Ibuki, Yuji Murakami, Ikuno Nishibuchi, Yasushi Nagata, Takaoki Furukawa, Tomoaki Kurokawa, Manato Ohsawa, Toru Yoshikawa and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yoichi HamaiDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan. yyhamai@hotmail.com.
Manabu EmiDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Yuta IbukiDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Yuji MurakamiDepartment of Radiation Oncology, Hiroshima University, Hiroshima, Japan.
Ikuno NishibuchiDepartment of Radiation Oncology, Hiroshima University, Hiroshima, Japan.
Yasushi NagataDepartment of Radiation Oncology, Hiroshima University, Hiroshima, Japan.
Takaoki FurukawaDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Tomoaki KurokawaDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Manato OhsawaDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Toru YoshikawaDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Morihito OkadaDepartment of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Hiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe degree of metabolic activity in tumor cells can be determined by 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET). Associations between FDG uptake by primary tumors of locally advanced esophageal squamous cell carcinoma (ESCC) under trimodal therapy and the pathological features of such tumors have not been fully investigated. PATIENTS AND

methodsWe evaluated relationships between the maximal standardized uptake (SUVmax) in primary tumors on preoperative PET images and pathological features as well as cancer recurrence in 143 patients with ESCC who underwent neoadjuvant chemoradiotherapy (NCRT) followed by surgery.

resultsThe post-SUVmax significantly differed after NCRT for ypT and ypN status, lymphatic invasion (LI), venous invasion (VI), and recurrence. Furthermore, the %ΔSUVmax (rate of decrease between before and after NCRT) for LI, VI, and recurrence significantly differed. Univariate and multivariate analyses selected post-SUVmax and %ΔSUVmax as independent preoperative predictors of recurrence-free survival [hazard ratio (HR) 1.46; 95% confidence interval (CI) 1.24-1.72 and HR 0.97; 95% CI 0.96-0.99, respectively; p < 0.001 for both]. Recurrence-free and overall survival were significantly stratified according to optimal SUVmax cutoffs for predicting recurrence (post- and %ΔSUVmax: 2.8 and 70, respectively).

conclusionsThe post- and %ΔSUVmax of primary tumors were significantly associated with the pathological features and recurrence of ESCC under trimodal therapy. Therefore, FDG-PET can preoperatively predict the degree of aggressive tumor behavior in ESCC under trimodal therapy.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaFluorodeoxyglucose F18Neoplasm Recurrence, LocalRadiopharmaceuticalsChemoradiotherapyHumansNeoadjuvant TherapyPositron-Emission TomographyPredictive Value of TestsFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID32405978
OpenAlexW3024977265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.